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increasing	 remdesivir	 prescriptions	 worldwide.	 However,	 potential	 cardiovas-
cular	(CV)	toxicities	associated	with	remdesivir	remain	unknown.	We	aimed	to	
characterize	 the	CV	adverse	drug	reactions	 (ADRs)	associated	with	remdesivir	
using	 VigiBase,	 an	 individual	 case	 safety	 report	 database	 of	 the	 World	 Health	
Organization	 (WHO).	Disproportionality	analyses	of	CV-	ADRs	associated	with	
remdesivir	were	performed	using	reported	odds	ratios	and	information	compo-

















WHAT QUESTION DID THIS STUDY ADDRESS?
This	study	identifies	CV	ADRs	associated	with	remdesivir	by	disproportionality	
analysis	using	VigiBase,	a	global	individual	case	safety	report	database.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
This	study	identifies	three	previously	unreported	putative	adverse	CV	reactions,	
namely,	hypotension,	cardiac	arrest,	and	bradycardia,	independently	associated	












and	 open-	label	 trials	 have	 shown	 that	 remdesivir	 treat-
ment	lowered	the	median	recovery	time	of	patients	with	
COVID-	19,6–	8	 with	 some	 trials	 demonstrating	 decreased	
mortality.6	 Based	 on	 this	 supporting	 evidence,	 the	 US	
Food	 and	 Drug	 Administration	 (FDA)	 approved	 rem-
desivir	as	 the	 first	drug	 treatment	against	COVID-	19	on	
October	22,	2020.9
Although	 the	 efficacy	 of	 remdesivir	 has	 been	 exten-
sively	investigated,	the	associated	adverse	events	(AEs)	are	
not	well-	characterized.	Because	remdesivir	has	not	been	
extensively	 used	 in	 clinical	 practice—	other	 than	 against	
Ebola	 virus	 (EBOV)	 disease	 and	 COVID-	19—	sufficient	
safety	 evidence	 has	 not	 been	 accumulated.	 At	 present,	
clinical	 trials	 on	 COVID-	19	 are	 the	 sole	 source	 of	 infor-
mation	on	cardiovascular	(CV)	toxicities	associated	with	
remdesivir,	 and	 recent	 RCTs	 have	 reported	 conflicting	
results;	some	RCTs	have	reported	that	remdesivir	causes	
more	 serious	CV	AEs	 than	 the	 standard	care,10	whereas	
another	 suggested	 that	 the	 CV	 AEs	 induced	 by	 remde-
sivir	is	comparable	to	that	induced	by	placebo.8	Although	
RCTs	 provide	 reliable	 information	 on	 drug	 efficacy,	 ob-
servational	 studies	 with	 large	 sample	 size	 often	 outper-
form	RCTs	in	capturing	rare	but	fatal	AEs,	such	as	cardiac	
arrest	 or	 myocardial	 infarction.11	 The	 increasing	 use	 of	




Therefore,	 we	 conducted	 a	 large	 observational	 phar-
macovigilance	study	using	the	World	Health	Organization	
(WHO)	 global	 database	 of	 individual	 case	 safety	 reports	
(ICSRs),12	 to	detect	CV	signals	with	high	resolution	and	
characterize	 the	CV	AEs	of	remdesivir.	The	VigiBase	 in-
corporates	 the	data	of	20 million	 individuals	 from	more	
than	130	countries	and	as	the	largest	pharmacovigilance	
database,	 it	 provides	 discriminating	 findings	 on	 drug	
safety,	as	indicated	in	our	previous	studies.13–	16
METHODS
Study design and data source
This	 large	 retrospective	 pharmacovigilance	 cohort	 study	
was	conducted	using	data	from	VigiBase,	the	WHO	global	





International	 Drug	 Monitoring	 (MDR),	 and	 is	 managed	
by	 the	 Uppsala	 Monitoring	 Center	 (UMC,	 Sweden).	





companies,	 and	 the	 sources	 are	 generally	 provided	 with	
postmarketing	 notifications.	 We	 extracted	 remdesivir-	
associated	 ADR	 cases	 from	 the	 inception	 of	 the	 data-
base	to	August	30,	2020.	The	ethics	committee	of	Yonsei	





Procedures and description of the 
pharmacovigilance cohort
As	 per	 the	 Medical	 Dictionary	 for	 Drug	 Regulatory	
Activities	(MedDRA)	version	23.1	(Table S1),	all	relevant	
CV-	ADRs	 classified	 by	 group	 queries	 were	 prespecified	
with	 remdesivir	 usage	 after	 sensitivity	 analysis	 and	 adjustment	 for	 multiple	
confounders.
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and	extracted	for	analysis.	Currently,	there	is	a	consider-
able	lack	of	specific	CV	toxicity	reports	on	remdesivir	for	




data.	 Consequently,	 we	 used	 some	 specific	 cardiac	 and	




drug	 information	 (indications,	 dosage,	 regimen,	 admin-
istration	route,	and	duration	prescribed),	ADR	(reported	
AE,	 MedDRA	 classification	 terms,	 time	 to	 onset,	 nature	
and	severity	of	ADR,	fetal	outcomes,	and	mortality),	and	
general	 administrative	 information	 (date	 of	 report,	 re-











to	 involve	 myocardial	 injury	 and	 further	 challenges	 the	




COVID-	19	 diagnosed	 population,	 offsetting	 the	 effect	 of	




As	 VigiBase	 incorporates	 a	 dataset	 comprising	 a	 large	
sample	size	collected	worldwide,	it	provides	a	good	fit	for	
the	study	of	disproportionality	(also	known	as	case–	non-	
case	 analysis),	 for	 which	 sufficient	 sample	 size	 is	 indis-
pensable	 to	 warrant	 applicable	 power	 and	 resolution.20	
We	 used	 the	 analysis	 to	 determine	 whether	 the	 propor-
tion	of	CV	toxicities	reported	for	remdesivir	differs	from	









than	0	or	 lower	confidence	 interval	 (CI)	of	ROR	greater	
than	1	indicates	significant	associations	of	specific	ADRs	
with	the	drugs.	ROR	was	calculated	using	the	chi-	square	
(χ2)	 test	 as	 per	 the	 well-	established	 reporting	 method	 of	
pharmacovigilance	studies.21	When	the	full	database	was	
not	 used	 as	 a	 comparator	 and	 sensitivity	 analyses	 were	




and	 multiple	 COVID-	19	 treatment	 drugs,	 including	 hy-
droxychloroquine,	corticosteroid,	lopinavir-	ritonavir,	and	
interferon.22,23	 Dexamethasone,	 hydrocortisone,	 predni-
solone,	 and	 prednisone	 were	 included	 for	 corticosteroid	




Bayesian	 neural	 network	 method	 developed	 by	 UMC.25	
Probabilistic	 logic	 in	 intelligent	 systems—	proven	 useful	






for	 large-	scale	 pattern	 exploration.26	This	 sensitive	 algo-
rithm	allows	the	identification	of	signals	soon	after	drug	










for	 the	 effect	 irrespective	 of	 drug,	 respectively.25,26	 Ntotal	
correspond	to	the	total	number	of	case	reports	in	the	full	
database.	 Qualitative	 variables	 were	 described	 as	 count	
(percentage),	 and	 continuous	 variables	 were	 expressed	
as	median	with	interquartile	range	(IQR).	The	remdesivir	
and	 full	 database	 cases	 were	 compared	 using	 the	χ2	 test	
IC = log2([Nobserved + 0.5]∕[Nexpected + 0.5])
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or	Fisher’s	exact	test	for	qualitative	variables	and	the	un-





less	 than	 0.05	 was	 considered	 significant.	 All	 analyses	
were	conducted	using	IBM	statistical	package	for	the	so-
cial	sciences	(SPSS)	version	25.0	(SPSS	Inc.)	or	R	software,	
version	 3.6.0	 (R	 Foundation	 for	 Statistical	 Computing).	
Power	 analyses	 were	 performed	 with	 G*Power,	 version	
3.1.9.6	(Heinrich-	Heine-	Universität-	Düsseldorf).
Generation of human pluripotent stem 
cells- derived cardiomyocytes
The	 human	 pluripotent	 stem	 cells	 (hPSCs)	 lines,	 which	
include	 both	 human	 embryonic	 stem	 cells	 (hESC:	 H9:	
Wicell)	and	human-	induced	pluripotent	 stem	cells	 (hiP-
SCs:	 CMC-	hiPSC-	011:	 KNIH)	 were	 maintained	 with	 the	
StemMACS	 iPS-	BREW	 XF,	 human	 (Miltenyi	 Biotec)	 on	














ability	 was	 determined	 using	 the	 CellTiter	 96	 AQueous	























19-	positive	 for	 all	 reported	 patients.	 Post	 hoc	 power	













tricular	 fibrillation	 (ROR:	22.1,	95%	CI:	10.4–	47.1,	 IC0.25:	













Remdesivir-	associated	 CV	 toxicity	 is	 a	 novel	 clinical	 en-
tity	 and	 represents	 a	 new	 problem	 for	 clinicians	 treating	
COVID-	19,	and,	 therefore,	 additional	data	were	collected	
to	facilitate	the	description	of	the	clinical	characteristics	of	
remdesivir-	associated	 CV-	ADR	 in	 the	 2107	 identified	 pa-
tients	 (Table 3).	All	CV-	ADRs	associated	with	remdesivir	
occurred	 more	 frequently	 in	 male	 patients	 (51.6%-	90.0%)	
than	in	female	patients.	Cardiac	arrest,	cardiogenic	shock,	
6 |   JUNG et al.




Full database (since 
February 2020) ROR (95% CI)
Total	numbers	of	ICSRs	available 2107 22,728,189 1,403,532
Numbers	of	ICSRs	by	cardiovascular	ADR	subgroups
Cardiac	arrest 93 (4.41) 83,581 (0.37) 3.50/3.19 3340 (0.24) 19.9 (16.1– 24.5)
Bradycardia 79 (3.75) 90,496 (0.40) 3.16/2.83 3703 (0.26) 15.0 (12.0– 18.9)
Cardiogenic	shock 19 (0.90) 16,292 (0.07) 3.28/2.56 737 (0.05) 17.8 (11.2– 28.1)
Hypotension 86 (4.08) 215,210 (0.95) 2.01/1.76 10,194 (0.73) 5.9 (4.7– 7.3)
Atrial	fibrillation 28 (1.33) 60,278 (0.27) 2.23/1.64 2624 (0.19) 7.3 (5.0– 10.6)
Ventricular	tachycardia 10 (0.47) 13,208 (0.06) 2.61/1.58 385 (0.03) 17.8 (9.5– 33.4)
Ventricular	fibrillation 7 (0.33) 9482 (0.04) 2.44/1.18 218 (0.02) 22.1 (10.4– 47.1)
Acute	myocardial	infarction 9 (0.43) 17,645 (0.08) 2.15/1.06 397 (0.03) 15.5 (8.0– 30.0)
Sinus	tachycardia 19	(0.90) 213,580	(0.94) −0.06/−0.78 10,467	(0.75) NA
Hypertension 13	(0.62) 176,559	(0.78) −0.32/−1.21 7910	(0.56) NA
Pulmonary	embolism 10	(0.47) 75,522	(00.33) 0.49/−0.54 2074	(0.15) NA
Chest	pain 7	(0.33) 319,538	(1.41) −2.00/−3.27 23,265	(1.66) NA
Electrocardiogram	QT	corrected	
interval	prolonged
4	(0.19) 21,278	(0.09) 0.86/−0.87 1746	(0.12) NA
Ischemic	stroke 3	(0.14) 9860	(0.04) 1.31/−0.74 429	(0.03) NA
Systolic	dysfunction 2	(0.09) 970	(0.00) 2.08/−0.51 189	(0.01) NA
Atrial	flutter 2	(0.09) 5118	(0.02) 1.36/−1.22 200	(0.01) NA
Supraventricular	tachycardia 2	(0.09) 8478	(0.04) 0.96/−1.63 249	(0.02) NA
Bundle	branch	block	right 2	(0.09) 2731	(0.01) 1.73/−0.86 105	(0.01) NA
Jugular	vein	thrombosis 2	(0.09) 1010	(0.00) 2.07/−0.51 29	(0.00) NA
Vertebral	artery	obstruction 1	(0.05) 123	(0.00) 1.55/−2.55 5	(0.00) NA
Cerebral	hemorrhage 1	(0.05) 36,338	(0.16) −1.37/−5.16 1373	(0.01) NA
Deep	vein	thrombosis 1	(0.05) 58,504	(0.26) −1.98/−5.78 1276	(0.01) NA
Lacunar	infarction 1	(0.05) 1543	(0.01) 1.22/−2.58 20	(0.00) NA
Right	ventricle	dysfunction 1	(0.05) 405	(0.00) 1.48/−2.32 31	(0.00) NA
Sinus	node	dysfunction 1	(0.05) 1972	(0.01) 1.13/−2.66 34	(0.00) NA
Transient	ischemic	attack 1	(0.05) 24,093	(0.11) −0.87/−4.66 653	(0.05) NA
Atrioventricular	block 1	(0.05) 8770	(0.04) 0.19/−3.61 232	(0.02) NA
Right	ventricular	failure 1	(0.05) 7102	(0.03) 0.37/−3.43 195	(0.01) NA
Coronary	artery	stenosis 1	(0.05) 2651	(0.01) 1.01/−2.79 38	(0.00) NA
Carotid	artery	occlusion 1	(0.05) 1994	(0.01) 1.13/−2.67 51	(0.00) NA
ST	segment	elevation 1	(0.05) 1837	(0.01) 1.16/−2.64 67	(0.00) NA
Hypertensive	urgency 1	(0.05) 132	(0.00) 1.55/−2.25 16	(0.00) NA
Torsade	de	pointes 1	(0.05) 5583	(0.02) 0.56/−3.24 154	(0.01) NA
Myocarditis 1	(0.05) 7340	(0.03) 0.34/−3.45 411	(0.03) NA
Pulmonary	hypertension 1	(0.05) 16,720	(0.07) −0.45/−4.25 514	(0.04) NA
Syncope 1	(0.05) 124,759	(0.55) −3.00/−6.81 4259	(0.30) NA
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The	overlaps	between	 identified	CV-	ADRs	are	 shown	 in	
Figure 1	and	Table 4.	AMI	cases	were	 frequently	associ-
ated	with	concurrent	conditions	(Table 4),	such	as	cardiac	
arrest	 (33.3%)	 and,	 in	 rare	 cases,	 ventricular	 tachycar-
dia	 (11.1%).	 Ventricular	 fibrillation	 was	 often	 associ-
ated	 with	 cardiac	 arrest	 (42.8%).	 Most	 of	 these	 eight	 CV	
events	occurred	with	other	serious	ADRs,	except	for	atrial	
fibrillation.
Remdesivir induced cardiotoxicity on 
hPSC- CMs in vitro
To	examine	whether	remdesivir	could	 induce	cardiotox-
icity	 in	 the	 human	 heart	 within	 the	 range	 of	 half	 maxi-
mal	effective	antiviral	concentration	 (EC50),	 the	culture	
hPSC-	CMs	 were	 treated	 with	 increasing	 concentrations	
of	remdesivir,	and	the	cell	viability	was	measured	at	24 h	
and	48 h	after	treatment	using	cell	proliferation	assay.	We	
observed	 that	 remdesivir	 treatment	 induced	 substantial	
cytotoxic	 effects	 in	 CMs	 derived	 from	 both	 hESCs	 and	
hiPSCs	(Figure 2).	In	addition,	treatment	with	remdesivir	
for	a	longer	time	(48 h)	demonstrated	significantly	lower	
cell	 viability	 of	 hPSCS-	CMs	 as	 compared	 to	 24  h	 post-	
treatment,	 indicating	time-	and	dose-	dependent	reaction	
and	potential	induced	cardiotoxicity	by	remdesivir.	These	




first	 drug	 to	 treat	 hospitalized	 patients	 with	 COVID-	19,	
and	the	approval	may	have	rapidly	increased	remdesivir	
use	worldwide.	The	large	increase	in	remdesivir	demand	
and	 associated	 ADR	 reports	 warrant	 urgent	 pharma-
covigilant	 evaluations	 of	 this	 drug.28,29	 We	 conducted	 a	
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related	 to	 remdesivir	 using	 the	 international	 pharma-
covigilance	database	(VigiBase),	which	includes	informa-
tion	 from	 over	 130	 countries	 and	 20  million	 individuals	
until	September	1,	2020.	To	the	best	of	our	knowledge,	this	
is	the	first	population-	based	pharmacovigilance	study	on	





F I G U R E  1  Overlap	between	
cardiovascular	entities.	AMI,	acute	
myocardial	infarction











Cardiac	arrest	(n	=	93) 2/93	(2.2) 2/93	(2.2) 3/93	(3.2) 3/93	(3.2)
Atrial	fibrillation	(n	=	28) 2/28	(7.1) 0/28	(0.0) 0/28	(0.0) 0/28	(0.0)
Ventricular	tachycardia	(n	=	10) 2/10 (20.0) 0/10	(0.0) 1/10	(10.0) 1/10	(10.0)
Acute	myocardial	infarction	(n	=	9) 3/9 (33.3) 0/9	(0.0) 1/9	(11.1) 0	(0.0)
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outcomes;	these	were	cardiac	arrest,	bradycardia,	shock,	
hypotension,	 atrial	 fibrillation,	 ventricular	 tachycardia,	
ventricular	fibrillation,	and	AMI	(Table 1).	To	distinguish	
drug-	induced	CV-	ADRs	 from	COVID-	19-	induced	CV	ef-














dycardia,	 and	 severe	 hypotension	 was	 reported	 to	 be	 as	
high	as	3.58%,	3.64%,	and	3.97%,	respectively,	in	patients	
with	 COVID-	19	 taking	 remdesivir,	 whereas	 they	 were	








total	 number	 of	 remdesivir	 users	 in	 VigiBase	 (2107	 pa-
tients)	 corresponds	 to	 a	 total	 number	 of	 any	 ADRs	 re-








transmission	 potential.32	 Early	 studies	 mainly	 focused	
on	 the	 efficacy	 of	 remdesivir	 against	 SARS	 and	 EBOV,	
because	it	protected	primate	kidney	epithelial	cells	 from	










treatment.28	 In	 addition,	 parallel	 studies	 evaluating	 its	
effectiveness	 in	 reducing	 mortality	 and	 time-	to-	recovery	
have	been	conducted.8,10,30




compared	 to	 other	 repurposed	 drug	 agents	 used	 to	 man-
age	COVID-	19.	To	date,	a	few	clinical	trials	have	reported	














in	patients	 taking	 remdesivir	are	caused	by	adverse	 reac-
tions	 of	 remdesivir	 or	 by	 severe	 COVID-	19.	 To	 confirm	
the	biological	causation,	we	designed	in	vitro	experiments	




potency	 for	 reducing	 cell	 viability,	 whereas	 less	 likely	 to	







to	 clinical	 settings,	 they	 provided	 a	 biological	 plausibility	
for	our	observational	findings.	Altogether,	our	findings	at	








minimize	 the	 confounding	 effect	 on	 CV	 outcomes	 by	 the	
nature	of	COVID-	19,	some	degrees	of	confounding	may	per-
sist	as	a	bias.	Remdesivir	trials	have	demonstrated	greatest	
12 |   JUNG et al.















































of	 potential	 CV	 consequences	 following	 remdesivir	 use,	
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